Insights into the development of Anti-metastatic therapy for mesenchymal tumors (GIST, RMS and LMS): EMSY increases the expression of tumor suppressor DMD (dystrophin) via down regulation of its target gene, 27/May/2014, 6.17 am

Molecular mechanisms of tumorigenesis: N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) suppresses the expression of tumor suppressor TIMP3 via up regulation of its target gene, 27/May/2014, 6.02 am
May 27, 2014
The effect of physical exercise on cardiovascular diseases: Mechanical Stretch Suppresses the expression of bio-marker of acute myocardial infarction, 27/May/2014, 6.53 am
May 27, 2014
Show all

A recent study from the Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA reveals that Dystrophin (DMD) is a tumor suppressor in human cancers and myogenic programs.

This study was published in the May 4 2014 Nature Genetics (One of the top journal in Genetics with an IF of  of  35.209) by Prof. Dr Jonathan A FletcherYuexiang Wang and others from the  Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Children’s Hospital, Boston, Massachusetts, USA; Genetic Diagnostic Laboratory, Department of Laboratory Medicine, Children’s Hospital, Boston, Massachusetts, USA; Department of Laboratory Medicine, Shanghai Children’s Medical Center, Jiaotong University, Shanghai, China; Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan; Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Molecular Diagnostics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Department of Pathology, Stanford University Medical Center, Stanford, California, USA; Department of Surgery, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; Ludwig Center at Harvard, Harvard Medical School and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA;  Enteric Neuroscience Program, Mayo Clinic, Rochester, Minnesota, USA; and Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Insights into the development of Anti-metastatic therapy for mesenchymal tumors (GIST, RMS and LMS): EMSY increases the expression of tumor suppressor DMD (dystrophin) via down regulation of its target gene. This study suggests that EMSY, by increasing the expression of DMD through down regulation of its target gene, it could inhibit the proliferation of mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS).  Together, this study suggests that “EMSY activators” may find their use in clinic in the treatment of mesenchymal tumors

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Insights into the development of Anti-metastatic therapy for mesenchymal tumors (GIST, RMS and LMS): EMSY increases the expression of tumor suppressor DMD (dystrophin) via down regulation of its target gene, 27/May/2014, 6.18 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.